Is Sarepta Therapeutics (NASDAQ:SRPT) a Sell? What does Credit Suisse Think?

September 7, 2018 - By Catherine Diaz

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Logo

Investors sentiment decreased to 0.97 in 2018 Q1. Its down 0.25, from 1.22 in 2017Q4. It dropped, as 31 investors sold Sarepta Therapeutics, Inc. shares while 81 reduced holdings. 45 funds opened positions while 64 raised stakes. 54.74 million shares or 3.52% more from 52.88 million shares in 2017Q4 were reported.

Fisher Asset Mgmt Limited Liability invested in 0% or 57,431 shares. Castleark Mgmt Ltd Liability Corporation accumulated 0.24% or 103,178 shares. Public Employees Retirement Association Of Colorado reported 0.01% stake. L S Advsrs reported 11,813 shares stake. State Of Wisconsin Inv Board accumulated 59,000 shares. Wellington Mgmt Group Incorporated Llp owns 0% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 15,981 shares. Sivik Glob Healthcare holds 1.04% or 30,000 shares. Pdt Prtn Lc has invested 1.04% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Daiwa Secs accumulated 0% or 357 shares. Oppenheimer holds 0.04% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 21,100 shares. Driehaus Limited Liability Corp reported 54,529 shares. Neuberger Berman Limited Liability Corporation holds 25,178 shares or 0% of its portfolio. Price T Rowe Assoc Md has 3.40 million shares. 327,698 are held by Sectoral Asset Management. The Switzerland-based Gam Ag has invested 0.06% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT).

Since June 27, 2018, it had 1 insider purchase, and 2 insider sales for $12.41 million activity. 16,000 shares were bought by INGRAM DOUGLAS S, worth $2.00 million on Wednesday, August 15. $9.78 million worth of stock was sold by Barry Richard on Wednesday, June 27.

Why Has Credit Suisse Given Sarepta Therapeutics (NASDAQ:SRPT) a $178 Price Target

Equity analysts at Credit Suisse began coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a note shared with investors and clients on Thursday morning. The broker set Outperform rating on the stock. Credit Suisse’s target price of $178 suggests potential of 25.84 % from the stock’s last close price.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Ratings Coverage

Among 15 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 14 have Buy rating, 0 Sell and 1 Hold. Therefore 93% are positive. Sarepta Therapeutics has $267 highest and $76.0 lowest target. $154.08’s average target is 8.93% above currents $141.45 stock price. Sarepta Therapeutics had 25 analyst reports since March 7, 2018 according to SRatingsIntel. As per Wednesday, March 7, the company rating was maintained by SunTrust. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “Outperform” rating given on Friday, May 4 by Credit Suisse. H.C. Wainwright maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Monday, March 12 with “Buy” rating. The firm earned “Outperform” rating on Tuesday, March 13 by Leerink Swann. Nomura maintained it with “Buy” rating and $13100 target in Tuesday, June 5 report. The firm has “Equal-Weight” rating given on Wednesday, June 20 by Morgan Stanley. The stock has “Buy” rating by Cowen & Co on Wednesday, June 20. Barclays Capital maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Wednesday, June 20 with “Buy” rating. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “Overweight” rating given on Friday, May 11 by Barclays Capital. As per Thursday, June 21, the company rating was maintained by Nomura.

The stock increased 0.49% or $0.69 during the last trading session, reaching $141.45. About 1.08M shares traded. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 197.08% since September 7, 2017 and is uptrending. It has outperformed by 184.51% the S&P500.

Analysts await Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to report earnings on October, 24. They expect $-0.89 earnings per share, down 14.10 % or $0.11 from last year’s $-0.78 per share. After $-0.66 actual earnings per share reported by Sarepta Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 34.85 % negative EPS growth.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA therapeutics for the treatment of rare neuromuscular diseases. The company has market cap of $9.40 billion. The firm offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy , which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It currently has negative earnings. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD.

More notable recent Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news were published by: Finance.Yahoo.com which released: “7 Strong Buy Stocks With 30%+ Upside Potential” on August 23, 2018, also Benzinga.com with their article: “Mark Connolly” published on September 06, 2018, Benzinga.com published: “Benzinga’s Top Upgrades, Downgrades For September 6, 2018” on September 06, 2018. More interesting news about Sarepta Therapeutics, Inc. (NASDAQ:SRPT) were released by: Seekingalpha.com and their article: “United Rentals Should Go Up – Cramer’s Lightning Round (8/16/18)” published on August 17, 2018 as well as Nasdaq.com‘s news article titled: “Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)” with publication date: August 31, 2018.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.